

Toronto General Hospital ANTIBIOGRAM Transplant Unit January 1, 2016 - December 31, 2016

Blood Isolates – % Susceptible

| | # | % | Ampicillin | Amoxicillin-Clavulanic acid | Penicillin | Piperacillin-Tazobactam | Meropenem | Ertapenem | Cloxacillin | Cefazolin | Ceftriaxone | Ceftazidime | Clindamycin | Erythromycin | Doxycycline | Ciprofloxacin | Moxifloxacin | Trimethoprim-Sulfamethoxazole | Gentamicin | Tobramycin | Amikacin | Vancomycin | Linezolid |
|--|---|---|------------|-----------------------------|------------|-------------------------|-----------|-----------|-------------|-----------|-------------|-------------|-------------|--------------|-------------|---------------|--------------|-------------------------------|------------|------------|----------|------------|-----------|
| | | | | | | | | | | | | | | | | | | | | | | | |

≥80% Susceptible ■
 70-79% Susceptible ■
 ≤69% Susceptible ■

| | | | | | | | | | | | | | | | | | | | | | | | | |
|---------------------|----|---|---|----|--|----|----|----|--|----|----|--|--|--|--|--|--|----|--|--|--|--|--|--|
| ALL BACTERIA | 34 | — | 6 | 26 | | 56 | 56 | 56 | | 38 | 50 | | | | | | | 52 | | | | | | |
|---------------------|----|---|---|----|--|----|----|----|--|----|----|--|--|--|--|--|--|----|--|--|--|--|--|--|

| | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------------------------------|----|-----|---|-----|--|-----|-----|-----|--|----|-----|-----|--|--|--|-----|--|-----|-----|-----|-----|--|--|--|--|
| ALL GRAM-NEGATIVE BACTERIA | 10 | 100 | | 70 | | 70 | 90 | 90 | | 30 | 70 | 70 | | | | 70 | | 70 | 90 | 70 | 100 | | | | |
| <i>Klebsiella pneumoniae</i> | 5 | 50 | 0 | 80 | | 80 | 80 | 80 | | 60 | 80 | 80 | | | | 80 | | 80 | 100 | 80 | 100 | | | | |
| <i>Escherichia coli</i> | 2 | 20 | 0 | 50 | | 50 | 100 | 100 | | 0 | 50 | 50 | | | | 0 | | 0 | 50 | 0 | 100 | | | | |
| <i>Klebsiella oxytoca</i> | 2 | 20 | 0 | 100 | | 100 | 100 | 100 | | 0 | 100 | 100 | | | | 100 | | 100 | 100 | 100 | 100 | | | | |
| <i>Enterobacter cloacae</i> | 1 | 10 | 0 | 0 | | 0 | 100 | 100 | | 0 | 0 | 0 | | | | 100 | | 100 | 100 | 100 | 100 | | | | |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|---|----|-----|-----|-----|---|-----|-----|-----|-----|-----|----|--|-----|-----|-----|--|--|-----|--|--|--|--|-----|-----|
| ALL GRAM-POSITIVE BACTERIA | 24 | 100 | 8 | 8 | | 50 | 42 | 42 | 42 | 42 | 42 | | 43 | 43 | | | | 43 | | | | | 96 | |
| Coagulase-negative staphylococci | 18 | 75 | | | | 50 | 50 | 50 | 50 | 50 | 50 | | 50 | 50 | 100 | | | 50 | | | | | 100 | 100 |
| <i>Enterococcus faecalis</i> , all isolates | 2 | 8 | 100 | 100 | | 100 | | | | | | | | | | | | | | | | | 100 | |
| - vancomycin-susceptible | 2 | 8 | 100 | 100 | | 100 | | | | | | | | | | | | | | | | | 100 | |
| - vancomycin-resistant (VRE) | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | |
| <i>Staphylococcus aureus</i> , all isolates | 2 | 8 | | | | 50 | 50 | 50 | 50 | 50 | | | 50 | 50 | 100 | | | 50 | | | | | 100 | 100 |
| - methicillin-susceptible | 1 | 4 | | | | 100 | 100 | 100 | 100 | 100 | | | 100 | 100 | 100 | | | 100 | | | | | 100 | 100 |
| - methicillin-resistant (MRSA) | 1 | 4 | | | | 0 | 0 | 0 | 0 | 0 | | | 0 | 0 | 100 | | | 0 | | | | | 100 | 100 |
| <i>Enterococcus faecium</i> , all isolates | 1 | 4 | 0 | 0 | | 0 | | | | | | | | | | | | | | | | | 0 | |
| - vancomycin-susceptible | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | |
| - vancomycin-resistant (VRE) | 1 | 4 | 0 | 0 | | 0 | | | | | | | | | | | | | | | | | 0 | 100 |
| - vancomycin-susceptible (vanA+) | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | |
| Viridans group streptococci* | 1 | 4 | | | 0 | | | | | 0 | | | | | | | | | | | | | 100 | |

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report; however the total number of "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" listed includes these organisms.
- Reported susceptibilities for "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" reflect estimates only based on the weighted average of susceptibilities for all organisms included on this report as well as those that have been excluded, with assumptions made for those drugs for which susceptibilities were not tested.
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Year-Specific Notes:

- Only a limited number of coagulase negative staphylococci isolates were tested for susceptibilities. The vast majority of coagulase-negative staphylococci are susceptible to vancomycin. If you have any questions, please contact the UHN/MSH Department of Microbiology.

Organism-Specific Notes:

- * Viridans group streptococci: Please note that only a small proportion of these isolates were tested for susceptibilities. Please take this into consideration when interpreting the reported results.

**Toronto General Hospital ANTIBIOGRAM
Transplant Unit
January 1, 2016 - December 31, 2016**

Respiratory Isolates – % Susceptible

| | # | % | Antibiotics | | | | | | | | | | | | | | | | | | | | | | |
|--|----|-----|-------------|-----------------------------|------------|-------------------------|-----------|-----------|-------------|-----------|-------------|-------------|-------------|--------------|-------------|---------------|--------------|-------------------------------|------------|------------|----------|------------|-----------|--|--|
| | | | Ampicillin | Amoxicillin-Clavulanic acid | Penicillin | Piperacillin-Tazobactam | Meropenem | Ertapenem | Cloxacillin | Cefazolin | Ceftriaxone | Ceftazidime | Clindamycin | Erythromycin | Doxycycline | Ciprofloxacin | Moxifloxacin | Trimethoprim-Sulfamethoxazole | Gentamicin | Tobramycin | Amikacin | Vancomycin | Linezolid | | |
| ≥80% Susceptible ■ 70-79% Susceptible ■ ≤69% Susceptible ■ | | | | | | | | | | | | | | | | | | | | | | | | | |
| ALL BACTERIA | 24 | — | 4 | 33 | 67 | 21 | | | 10 | | | | | | | | 25 | | | | | | | | |
| ALL GRAM-NEGATIVE BACTERIA | 23 | 100 | 4 | 30 | 65 | 17 | | | 5 | 26 | | | | | 56 | 22 | 70 | 75 | 80 | | | | | | |
| <i>Pseudomonas aeruginosa</i> | 15 | 65 | | 33 | 60 | | | | | 33 | | | | | 73 | | 80 | 87 | 80 | | | | | | |
| <i>Escherichia coli</i> | 3 | 13 | 0 | 0 | 0 | 67 | 67 | | 0 | 0 | | | | | 0 | 0 | 0 | 0 | 67 | | | | | | |
| <i>Stenotrophomonas maltophilia</i> | 3 | 13 | | | | | | | | | | | | | 67 | 100 | | | | | | | | | |
| <i>Klebsiella pneumoniae</i> | 1 | 4 | 0 | 100 | 100 | 100 | 100 | | 100 | 100 | | | | | 100 | | 100 | 100 | 100 | 100 | | | | | |
| <i>Serratia marcescens</i> | 1 | 4 | 0 | 0 | 0 | 100 | 100 | | 0 | 0 | | | | | 100 | | 100 | 100 | 100 | 100 | | | | | |
| ALL GRAM-POSITIVE BACTERIA | 1 | 100 | | | 100 | 100 | 100 | 100 | 100 | 100 | | 100 | 100 | | | | 100 | | | | | 100 | | | |
| <i>Staphylococcus aureus</i> , all isolates | 1 | 100 | | | 100 | 100 | 100 | 100 | 100 | 100 | | | 100 | 100 | 100 | | 100 | | | | | 100 | 100 | | |
| - methicillin-susceptible | 1 | 100 | | | 100 | 100 | 100 | 100 | 100 | 100 | | | 100 | 100 | 100 | | 100 | | | | | 100 | 100 | | |
| - methicillin-resistant (MRSA) | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | |

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report; however the total number of "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" listed includes these organisms.
- Reported susceptibilities for "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" reflect estimates only based on the weighted average of susceptibilities for all organisms included on this report as well as those that have been excluded, with assumptions made for those drugs for which susceptibilities were not tested.
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Year-Specific Notes:

- Susceptibility for ceftazolin are not available for Gram-negative isolates from non-sterile site specimens for the current year.

Organism-Specific Notes:

- ‘ *S. maltophilia*: Susceptibility to moxifloxacin was predicted based on levofloxacin susceptibility testing results.

**Toronto General Hospital ANTIBIOGRAM
Transplant Unit
January 1, 2016 - December 31, 2016**

Skin, Wound and Abscess Isolates – % Susceptible

| | # | % | Antibiotics | | | | | | | | | | | | | | | | | | | | | |
|--|----|-----|-------------|-----------------------------|------------|-------------------------|-----------|-----------|-------------|-----------|-------------|-------------|-------------|--------------|-------------|---------------|--------------|-------------------------------|------------|------------|----------|------------|-----------|--|
| | | | Ampicillin | Amoxicillin-Clavulanic acid | Penicillin | Piperacillin-Tazobactam | Meropenem | Ertapenem | Cloxacillin | Cefazolin | Ceftriaxone | Ceftazidime | Clindamycin | Erythromycin | Doxycycline | Ciprofloxacin | Moxifloxacin | Trimethoprim-Sulfamethoxazole | Gentamicin | Tobramycin | Amikacin | Vancomycin | Linezolid | |
| ≥80% Susceptible ■ 70-79% Susceptible ■ ≤69% Susceptible ■ | | | | | | | | | | | | | | | | | | | | | | | | |
| ALL BACTERIA | 19 | — | 11 | 26 | 47 | 37 | 32 | | | 32 | | | | | | | 16 | | | | | | | |
| ALL GRAM-NEGATIVE BACTERIA | 9 | 100 | | 33 | 67 | 67 | 56 | | | 56 | 89 | | | | 67 | | | 78 | 63 | 100 | | | | |
| <i>Escherichia coli</i> | 4 | 44 | 0 | 75 | 75 | 100 | 100 | | | 100 | 100 | | | | 50 | | 0 | 50 | 50 | 100 | | | | |
| <i>Pseudomonas aeruginosa</i> | 3 | 33 | | | 67 | 33 | | | | | 100 | | | | 100 | | | 100 | 100 | 100 | | | | |
| <i>Klebsiella pneumoniae</i> | 1 | 11 | 0 | 0 | 0 | 0 | 0 | | | 0 | 0 | | | | 0 | | 0 | 100 | 0 | 100 | | | | |
| <i>Aeromonas hydrophila</i> | 1 | 11 | | 100 | 100 | 100 | 100 | | | 100 | 100 | | | | 100 | | 0 | 100 | | 100 | | | | |
| ALL GRAM-POSITIVE BACTERIA | 10 | 100 | 20 | 20 | 30 | 10 | 10 | 10 | 10 | 10 | | 20 | 20 | | | | 30 | | | | | 90 | | |
| <i>Enterococcus faecium</i> , all isolates | 4 | 40 | 0 | 0 | 0 | | | | | | | | | | | | | | | | | 75 | | |
| - vancomycin-susceptible | 3 | 30 | 0 | 0 | 0 | | | | | | | | | | | | | | | | | 100 | | |
| - vancomycin-resistant (VRE) | 1 | 10 | 0 | 0 | 0 | | | | | | | | | | | | | | | | | 0 | | |
| - vancomycin-susceptible (vanA+) | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | |
| Coagulase-negative staphylococci | 2 | 20 | | | 0 | 0 | 0 | 0 | 0 | | | 0 | 0 | 100 | | | 50 | | | | | 100 | | |
| <i>Enterococcus faecalis</i> , all isolates | 2 | 20 | 100 | 100 | 100 | | | | | | | | | | | | | | | | | 100 | | |
| - vancomycin-susceptible | 2 | 20 | 100 | 100 | 100 | | | | | | | | | | | | | | | | | 100 | | |
| - vancomycin-resistant (VRE) | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | |
| <i>Staphylococcus aureus</i> , all isolates | 2 | 20 | | | 50 | 50 | 50 | 50 | 50 | | | 100 | 100 | 50 | | | 100 | | | | | 100 | | |
| - methicillin-susceptible | 1 | 10 | | | 100 | 100 | 100 | 100 | 100 | | | 100 | 100 | 100 | | | 100 | | | | | 100 | | |
| - methicillin-resistant (MRSA) | 1 | 10 | | | 0 | 0 | 0 | 0 | 0 | | | 100 | 100 | 0 | | | 100 | | | | | 100 | | |

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report; however the total number of "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" listed includes these organisms.
- Reported susceptibilities for "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" reflect estimates only based on the weighted average of susceptibilities for all organisms included on this report as well as those that have been excluded, with assumptions made for those drugs for which susceptibilities were not tested.
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Year-Specific Notes:

- Susceptibility for cefazolin are not available for Gram-negative isolates from non-sterile site specimens for the current year.

Toronto General Hospital ANTIBIOGRAM Transplant Unit January 1, 2016 - December 31, 2016

Urine Isolates – % Susceptible

| | # | % | Antibiotics | | | | | | | | | | | | | | | | | | | |
|--|----|-----|-------------|-----------------------------|------------|-------------------------|-----------|-----------|-------------|-----------|------------|-------------|-------------|-------------|---------------|-------------------------------|----------------|------------|------------|----------|------------|-----------|
| | | | Ampicillin | Amoxicillin-Clavulanic acid | Penicillin | Piperacillin-Tazobactam | Meropenem | Ertapenem | Cloxacillin | Cefazolin | Cephalexin | Ceftriaxone | Ceftazidime | Doxycycline | Ciprofloxacin | Trimethoprim-Sulfamethoxazole | Nitrofurantoin | Gentamicin | Tobramycin | Amikacin | Vancomycin | Linezolid |
| ≥80% Susceptible ■ 70-79% Susceptible ■ ≤69% Susceptible ■ | | | | | | | | | | | | | | | | | | | | | | |
| ALL BACTERIA | 16 | — | 6 | 38 | | 38 | 81 | 75 | | | 19 | 44 | | | 50 | 25 | 44 | | | | | |
| ALL GRAM-NEGATIVE BACTERIA | 13 | 100 | 8 | 46 | | 46 | 100 | 92 | | | 23 | 54 | 54 | | 61 | 31 | 54 | 69 | 61 | 100 | | |
| <i>Escherichia coli</i> | 7 | 54 | 14 | 43 | | 43 | 100 | 100 | | | 14 | 57 | 57 | | 57 | 43 | 86 | 57 | 57 | 100 | | |
| <i>Klebsiella pneumoniae</i> | 3 | 23 | 0 | 67 | | 67 | 100 | 100 | | | 33 | 67 | 67 | | 100 | 33 | 33 | 100 | 100 | 100 | | |
| <i>Enterobacter cloacae</i> | 1 | 8 | 0 | 0 | | 0 | 100 | 0 | | | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 100 | | |
| <i>Proteus mirabilis</i> | 1 | 8 | 0 | 100 | | 100 | 100 | 100 | | | 100 | 100 | 100 | | 100 | 0 | 0 | 100 | 100 | 100 | | |
| <i>Serratia marcescens</i> | 1 | 8 | 0 | 0 | | 0 | 100 | 100 | | | 0 | 0 | 0 | | 0 | 0 | 0 | 100 | 0 | 100 | | |
| ALL GRAM-POSITIVE BACTERIA | 3 | 100 | | | | | | | | | | | | | | | | | | 67 | 100 | |
| <i>Enterococcus faecium</i> , all isolates | 3 | 100 | 0 | 0 | | 0 | | | | | | | | 0 | 0 | | 0 | | | 67 | 100 | |
| - vancomycin-susceptible | 2 | 67 | 0 | 0 | | 0 | | | | | | | | 0 | 0 | | 0 | | | 100 | 100 | |
| - vancomycin-resistant (VRE) | 1 | 33 | 0 | 0 | | 0 | | | | | | | | 0 | 0 | | 0 | | | 0 | 100 | |
| - vancomycin-susceptible (vanA+) | 0 | 0 | | | | | | | | | | | | | | | | | | | | |

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report; however the total number of "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" listed includes these organisms.
- Reported susceptibilities for "ALL BACTERIA", "ALL GRAM-NEGATIVE BACTERIA", and "ALL GRAM-POSITIVE BACTERIA" reflect estimates only based on the weighted average of susceptibilities for all organisms included on this report as well as those that have been excluded, with assumptions made for those drugs for which susceptibilities were not tested.
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Year-Specific Notes:

- Susceptibility for cefazolin are not available for Gram-negative isolates from non-sterile site specimens for the current year.